中国组织工程研究2017，Vol.21Issue(4)：499-504,6.DOI:10.3969/j.issn.2095-4344.2017.04.002
不同浓度厄贝沙坦对前成骨细胞分化和矿化的影响
Effects of different concentrations of irbesartan on the differentiation and mineralization of preosteoblasts
丁晓伟 1徐湲 2闵泽 1千勇洙 1何志丹 1徐洋 1刘倩倩 1赵忠海1
作者信息
- 1. 沈阳医学院附属中心医院，康复医学科，辽宁省沈阳市 110024
- 2. 沈阳医学院附属中心医院，中心实验室，辽宁省沈阳市 110024
- 折叠
摘要
Abstract
BACKGROUND:Angiotensin II receptor antagonists have been found to exerct a stronger protective effect on bone than angiotensin converting enzyme inhibitors. OBJECTIVE:To investigate the effect of different concentrations of irbesartan (angiotensin II receptor antagonist) on the differentiation and mineralization of mouse preosteoblasts. METHODS:Mouse preosteoblast cel lines MC3T3-E1 in logarithmic phase were selected and cultured in the osteogenic induction medium containing 0 (control group), 0.001, 0.01, 0.1 mmol/L irbesartan, respectively. Ten days later, the cel differentiation was observed by alkaline phosphatase staining. The mineralization was observed by alizarin red staining after 21 days of culture. mRNA expressions of osteocalcin, alkaline phosphatase and Runt-associated transcription factor 2 in osteoblasts were detected by real-time PCR at 1, 4, 7, 14 and 21 days of culture. RESULTS AND CONCLUSION:The activity of alkaline phosphatase in al the irbesartan groups (0, 0.001, 0.01, 0.1) was higher than that in the control group (P<0.05), which was the most obvious in 0.01 mmol/L. The number and area of calcium nodules in each irbesartan group were significantly higher than those in the control group (P<0.05), especial y in 0.01 mmol/L. Compared with the control group, 0.01 mmol/L irbesartan significantly upregulated the mRNA expressions of osteocalcin, alkaline phosphatase and Runt-associated transcription factor 2 (P<0.05). These results suggest that 0.01 mmol/L irbesartan significantly promotes the differentiation and mineralization of osteoblasts.关键词
组织构建/骨细胞/厄贝沙坦/成骨细胞/分化/矿化/碱性磷酸酶染色分类
医药卫生引用本文复制引用
丁晓伟,徐湲,闵泽,千勇洙,何志丹,徐洋,刘倩倩,赵忠海..不同浓度厄贝沙坦对前成骨细胞分化和矿化的影响[J].中国组织工程研究,2017,21(4):499-504,6.
